Irritable bowel syndrome: modern concepts and new possibilities of correction

Prof. T.D. Zvyagintseva, PHD S.V. Gridneva.

Kharkiv Medical Academy of Postgraduate Education.

The article deals with the pathogenetic mechanisms of formation of irritable bowel syndrome (IBS) according to Roman criteria IV (2016), shows the main causes of abdominal pain in IBS — increase visceral sensitivity of the colon and disturbance of its motility, presents the classification of IBS types, issues of diagnosis of this pathology in the light Rome Consensus IV (2016). The new approaches to the treatment of abdominal pain in IBS are covered with the use of peppermint oil and the efficacy of Isidu in patients with IBS with constipation.

Key Words: irritable bowel syndrome, Roman criteria, abdominal pain, constipation


1. Butorova LI, Kalinin AV. Sindrom razdrazhennogo kishechnika: patogeneticheskie podhody k lecheniju abdominal’noj boli [Irritable bowel syndrome: pathogenetic approaches to the treatment of abdominal pain]. Farmateka. 2011;12:8—10. Russian.
2. Dorofeev AJe, Rudenko NN. Maslo mjaty perechnoj vlechenii sindroma razdrazhennogo kishechnika. URL:
5. Polujektova EA, Kuchumova SJu, Sheptulin AA, Ivashkin VT. Lechenie sindroma razdrazhennogo kishechnika s pozicij sovremennyh predstavlenij o patogeneze zabolevanija [Treatment of irritable bowel syndrome from the standpoint of modern ideas about the pathogenesis of the disease]. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2013;1:57—65. Russian.
6. Adam D. Farmer, Qasim A. Gut pain and visceral hypersensitivity. Br J Pain. 2013;7(1): 39—47. doi: 10.1177/2049463713479229.
7. Amato A, Liotta R, Mule F. Effects of menthol on circularsmooth muscle of human colon: analysis of the mechanism of action. Eur J Pharmacol. 2014;740:295-301. doi: 10.1016/j.ejphar.2014.07.018.
8. Burke C. Understanding IBS. New York: Mahon Publishing Group; 2005. 112 p.
9. Camilleri M, Ford AC. Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. Handb Exp Pharmacol. 2017;239:75-113. doi: 10.1007/164_2016_102.
10. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023-34. doi: 10.1111/apt.12938.
11. Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable BowelSyndrome Symptoms. Dig Dis Sci. 2016;61(2):560-71. doi: 10.18103/imr.v3i9.565.
12. Devanarayana NM, Rajindrajith S, Benninga MA. Quality of life and health care consultation in 13 to 18 year olds with abdominal pain predominant functional gastrointestinal diseases. BMC Gastroenterol. 2014;14:150. doi: 10.1186/1471-230x-14-150.
13. Drossman DA, Hosier WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035.
14. Drossman D. A Functional gastrointestinal disorders: history,pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262-1279. doi: 10.1053/j.gastro.2016.02.032.
15. Haber SL, El-Ibiary SY. Peppermint oil for treatment of irritable bowel syndrome. Am J Health Syst Pharm. 2016;73(2):22-6. doi: 10.2146/ajhp140801.
16. Husain FM, Ahmad I, Khan MS, Tahseen Q, Shahnawaz Khan, Alshabib N. Sub-MICs of Menthapiperita essential oil and menthol inhibits AHL mediated quorum sensing and biofilm of Gram-negative bacteria. Fron Microbiol. 2015;6:420. doi: 10.3389/fmicb.2015.00420.
17. Lacy BE, Mearin F, Chang L, Chey W, Lembo A, Simrén M, Spiller R.Bowel Disorders. Gastroenterology. 2016;150:1393—1407. doi: 10.24890/mdcp.03.
18. Lewis ML, Palsson OS, Whitehead WE, van Tilburg MA. Prevalence of Functional Gastrointestinal Disordersin Children and Adolescents. J. Pediatr. 2016.17;177:39-43 doi: 10.1016/j.jpeds.2016.04.008.
19. Palsson OS, Whitehead WE, van Tilburg A, Spiegel B, Tack J, Walker L, Yang Y. Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterol. 2016;150(6):1481-1491. doi: 10.24890/gb.18.
20. Roshan N, Riley TV, Hammer KA. Antimicrobial activity of natural products against Clostridium difficile in vitro. J ApplMicrobiol. 2017;123:92-103. doi: 10.1111/jam.13486.
21. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents,antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;8:102-103. doi: 10.1002/14651858.cd003460.pub3.
22. Samber N, Khan A, Varma A, Manzoor N. Synergistic anti-candidal activity and mode of action of Mentha piperita essential oil and its major components. Pharm Biol. 2015;53(10):1496-504. doi: 10.3109/13880209.2014.989623.
23. Sanagapalli S, Agnihotri K, Leong R, Corte CJ. Antispasmodic drugs in colonoscopy: a review of their pharmacology, safety and efficacy in improving polyp detection and related outcomes. Therap Adv Gastroenterol. 2017;10(1):101-113. doi: 10.1177/1756283×16670076.
24. Schoenfeld PS. Advances in IBS 2016: A Review of Current and Emerging Data. Gastroenterol Hepatol (NY). 2016 Aug;12(8Suppl 3):1-11. PMID: 28070176, PMCID: PMC5210026
25. Mark F, Lawrence S, Laurence J. Brandt. Sleisenger and Fordtran’s Gastrointestinaland Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Elsevier, 2015. ISBN-13: 9781455746927